Study directory

Schizophrenia studies

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
4306studies shown
Showing 289-300 of 4,306
Drug study icon
RecruitingEUCTR 2017-001170-42

An adaptive Phase II/III, Double-Blind, Randomized, Placebo-controlled, Two-Part, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen® (sodium benzoate), a D-Amino Acid Oxidase In...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

Multiple locations, including Gdańsk
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugA study involving a medication or substance.
Countries
Poland
Sponsor
SyneuRx International (Taiwan) Corp
Condition
Schizophrenia
Drug study icon
RecruitingEUCTR 2022-000054-28

Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity (OligoTreat)

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

Multiple locations, including Augsburg
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Germany
Sponsor
Klinikum der Universität München
Condition
Schizophrenia
Drug study icon
RecruitingEUCTR 2022-001582-12

Open, multicenter, randomized clinical trial to evaluate the efficacy and safety of aripiprazole vs paliperidone / risperidone using multi-omics data in patients with a first psychotic episode.

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

Multiple locations, including Barcelona
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Spain
Sponsor
Consorcio Centro de Investigacion Biomedica en Red (CIBER)
Condition
Schizophrenia
Drug study icon
RecruitingNCT04478838

"Extended" (Alternate Day) Antipsychotic Dosing

This summary needs review. Please check the official study record and contact the research team for details.

In Toronto
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugOver 18 Years
Countries
Canada
Sponsor
Centre for Addiction and Mental Health
Condition
Schizophrenia
Drug study icon
RecruitingNCT07369154

52-week Open Label Safety-Tolerability Study

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Chandler
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years
Countries
United States
Sponsor
LB Pharmaceuticals Inc.
Condition
Schizophrenia
Drug study icon
RecruitingNCT07615426

Aticaprant for schizophrenia

The registry lists this study as recruiting. Study locations are listed in the United States.

Multiple locations, including Garden Grove
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 55 Years
Countries
United States
Sponsor
Janssen Research & Development, LLC
Condition
Schizophrenia
Drug study icon
RecruitingNCT07221877

Effect of KarXT on Urological Safety

The registry lists this study as recruiting. Study locations are listed in the United States.

Multiple locations, including Little Rock
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years
Countries
United States
Sponsor
Bristol-Myers Squibb
Condition
Schizophrenia
Drug study icon
RecruitingNCT03094429

Safety study of safety and Efficacy of NaBen®, in schizophrenia

The registry lists this study as recruiting. Study locations are listed in the United States.

In Pasadena
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 55 Years
Countries
United States
Sponsor
SyneuRx International (Taiwan) Corp
Condition
Schizophrenia
Drug study icon
RecruitingNCT04113993

Bazedoxifene -Treatment for Women With Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In Melbourne
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years
Countries
Australia
Sponsor
The Alfred
Condition
Schizophrenia
Behavioral study icon
RecruitingNCT06817980

Disorders of the Sense of Self and Physical Activity

This summary needs review. Please check the official study record and contact the research team for details.

In Strasbourg
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaBehavioralFrom 18 Years to 60 Years
Countries
France
Sponsor
University Hospital, Strasbourg, France
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.